FOLH1 and prostate cancer: Under this lens, the successful synthesis and application of [43Sc]Sc-PSMA-617 in vivo should exhibit specific uptake in PSMA-expressing tumors, such as those derived from the LNCaP and 22Rv1 prostate cancer cell lines, as well as PSMA-mediated uptake in the salivary glands [57,58,59,60,61].